Quantcast
Last updated on April 24, 2014 at 14:25 EDT

Latest Red blood cell Stories

2011-05-13 10:43:14

A cancer drug already used to treat adults and school-age children with sickle cell anemia is safe and significantly reduces pain and other complications of the disease in children as young as 9 months, according to a national study involving a UT Southwestern Medical Center researcher. Pediatric researchers at UT Southwestern and 13 other academic medical centers say hydroxyurea should be offered to all young children with sickle cell anemia, regardless of disease severity and clinical...

2011-05-10 12:47:41

Nitric oxide gas appears to directly impact the source of the classic, disabling pain crises of sickle cell disease, Georgia Health Sciences University researchers report. The short-acting gas helps unglue hemoglobin molecules that stick together, forming long chains that ultimately deform red blood cells and prompting a cellular pileup in small blood vessels and pain, said Dr. C. Alvin Head, Chairman of GHSU's Department of Anesthesiology. The findings get scientists closer to understanding...

2011-05-02 16:37:05

News tips from the 2011 Annual Meeting of the Pediatric Academic Societies, April 30-May 3, Denver, Colo. Pediatricians from Johns Hopkins Children's Center and elsewhere have discovered a link between low levels of vitamin D and anemia in children. The findings, presented on May 1 at the annual meeting of the Pediatric Academic Societies in Denver, Colo., show that vitamin D deficiency may play an important role in anemia. Anemia, which occurs when the body has too few oxygen-carrying red...

2011-04-28 21:16:01

Unraveled the molecular mechanism whereby sickle cell hemoglobin confers a survival advantage against malaria The latest issue of the journal Cell carries an article that is likely to help solve one of the long-standing mysteries of biomedicine. In a study that challenges currently held views, researchers at the Instituto Gulbenkian de Ciência (IGC), in Portugal, unravel the molecular mechanism whereby sickle cell hemoglobin confers a survival advantage against malaria, the...

2011-04-25 16:00:00

SAN DIEGO, April 25, 2011 /PRNewswire/ -- HemaQuest Pharmaceuticals, Inc. (HemaQuest), a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that clinical investigators have enrolled the first patient in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease. The study, which is being conducted by investigators in clinical sites in the US, Canada, Jamaica, Egypt and Lebanon, is expected to...

2011-04-21 14:48:18

Almost 3.3 billion people, half of the world's population, risk being infected with malaria. Despite having effective means against malaria, the WHO reports 250 million cases of malaria each year and more than 700,000 related deaths. Researchers at the University of Copenhagen have now discovered that EPO, the doping drug known from professional cycling, can significantly reduce cerebral malaria related deaths. When more than 700,000 people die from malaria each year it is due to two grave...

2011-04-19 13:00:00

SAN DIEGO, April 19, 2011 /PRNewswire/ -- Sangart, Inc., today announced that it recently received more than $50 million in new equity funding from existing investors, led by Leucadia National Corporation. The most recent investment brings the total funding raised by the company since its inception in 1998 to more than $230 million. This financing round also included warrants which, if exercised, could provide up to an additional $50 million in future funding. Funds raised in this Series...

2011-04-15 14:29:03

Medical literature addresses possible adverse effects with older red cells; delivery of oxygen In light of recent studies that suggest the use of stored blood during transfusions may cause adverse effects in patients, the National Heart, Lung, and Blood Institute (NHLBI) funded a number of research projects to examine the safety of transfusing older red cells and the impact of stored blood on respiratory gases. These papers discussing potential adverse effects of stored blood and related...

2011-03-14 12:09:00

CHICAGO, March 14, 2011 /PRNewswire/ -- Developed by inventor Lawrence F. Glaser and represented by ICAP Ocean Tomo, this technology will be auctioned off at ICAP Ocean Tomo's Spring 2011 Live IP Auction on March 31, 2011 in New York City. (Logo: http://photos.prnewswire.com/prnh/20100614/CG20517LOGO) Key Characteristics & Benefits This patent discloses the following: The use of genetically modified erythrocytes/red blood cells (RBC) for treating and preventing viral infections....

2011-03-09 14:58:46

Scientists are reporting an "important step" toward development of a universal blood product that would eliminate the need to "type" blood to match donor and recipient before transfusions. A report on the "immunocamouflage" technique, which hides blood cells from antibodies that could trigger a potentially fatal immune reaction that occurs when blood types do not match, appears in the ACS journal, Biomacromolecules. Maryam Tabrizian and colleagues note that blood transfusions require a...